Cellectar Biosciences Sees Top-Line Data From WM CLOVER-WaM Trial In 2H23; Remains On Target For 2024 Product Launch Assuming NDA Approval
Portfolio Pulse from Benzinga Newsdesk
Cellectar Biosciences anticipates top-line data from its WM CLOVER-WaM trial in the second half of 2023. The company remains on track for a product launch in 2024, assuming it receives New Drug Application (NDA) approval.
August 14, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cellectar Biosciences' stock may be influenced by the anticipated data from the WM CLOVER-WaM trial and the potential 2024 product launch.
The news directly pertains to Cellectar Biosciences' ongoing trial and potential product launch. These events could significantly impact the company's stock price, depending on the trial results and whether the NDA approval is granted. However, as these events are still some time away, the immediate impact on the stock price may be neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100